Atria Investments Inc Reduces Position in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Atria Investments Inc reduced its position in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 29.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,508 shares of the company’s stock after selling 6,415 shares during the period. Atria Investments Inc’s holdings in Takeda Pharmaceutical were worth $221,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Russell Investments Group Ltd. raised its holdings in Takeda Pharmaceutical by 65.2% during the first quarter. Russell Investments Group Ltd. now owns 10,676 shares of the company’s stock worth $148,000 after purchasing an additional 4,213 shares in the last quarter. O Shaughnessy Asset Management LLC lifted its position in Takeda Pharmaceutical by 43.2% in the first quarter. O Shaughnessy Asset Management LLC now owns 88,663 shares of the company’s stock valued at $1,232,000 after acquiring an additional 26,735 shares during the last quarter. Advisors Asset Management Inc. boosted its stake in Takeda Pharmaceutical by 7.1% in the first quarter. Advisors Asset Management Inc. now owns 49,781 shares of the company’s stock valued at $691,000 after acquiring an additional 3,315 shares in the last quarter. Cetera Advisors LLC purchased a new position in shares of Takeda Pharmaceutical during the first quarter worth about $240,000. Finally, Simplicity Wealth LLC increased its position in shares of Takeda Pharmaceutical by 4.0% during the second quarter. Simplicity Wealth LLC now owns 299,984 shares of the company’s stock worth $3,882,000 after purchasing an additional 11,449 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Stock Up 0.4 %

Shares of NYSE TAK opened at $13.38 on Friday. The business has a 50-day moving average price of $14.10 and a 200 day moving average price of $13.84. The stock has a market cap of $42.57 billion, a PE ratio of 23.07, a price-to-earnings-growth ratio of 0.25 and a beta of 0.54. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64. Takeda Pharmaceutical Company Limited has a 52-week low of $12.57 and a 52-week high of $15.08.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.